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Simple Summary: In the BRIDGES project, the breast/ovarian cancer gene RAD51D has been
sequenced in >113,000 women. In the present study, we focused on the impact that 11 pre-selected
RAD51D variants at the intron/exon boundaries had on the splicing process (intron removal). For
this purpose, we developed a splicing reporter minigene, containing RAD51D-exons 2–9 wherein
any variant could be introduced and functionally assayed for splicing alterations. All variants
impaired splicing, 10 of which caused complete splicing aberrations. Moreover, we developed a
minigene-based strategy to search for non-canonical, spliceogenic variants that disrupted splicing
enhancers/silencers in the non-constitutive exon 3. Twenty-six BRIDGES and 16 artificial exon
3 variants were also tested. Thirty variants impaired splicing by producing variable amounts of
the FL transcript. In total, up to 9 variants were classified as Likely Pathogenic, and therefore were
clinically actionable. Carriers may benefit from tailored prevention protocols and therapies.
Abstract: RAD51D loss-of-function variants increase lifetime risk of breast and ovarian cancer.
Splicing disruption is a frequent pathogenic mechanism associated with variants in susceptibility
genes. Herein, we have assessed the splicing and clinical impact of splice-site and exonic splicing
enhancer (ESE) variants identified through the study of ~113,000 women of the BRIDGES cohort.
A RAD51D minigene with exons 2–9 was constructed in splicing vector pSAD. Eleven BRIDGES
splice-site variants (selected by MaxEntScan) were introduced into the minigene by site-directed
mutagenesis and tested in MCF-7 cells. The 11 variants disrupted splicing, collectively generating
25 different aberrant transcripts. All variants but one produced negligible levels (<3.4%) of the
full-length (FL) transcript. In addition, ESE elements of the alternative exon 3 were mapped by
testing four overlapping exonic microdeletions (≥30-bp), revealing an ESE-rich interval (c.202_235del)
with critical sequences for exon 3 recognition that might have been affected by germline variants.
Next, 26 BRIDGES variants and 16 artificial exon 3 single-nucleotide substitutions were also assayed.
Thirty variants impaired splicing with variable amounts (0–65.1%) of the FL transcript, although only
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c.202G>A demonstrated a complete aberrant splicing pattern without the FL transcript. On the other
hand, c.214T>C increased efficiency of exon 3 recognition, so only the FL transcript was detected
(100%). In conclusion, 41 RAD51D spliceogenic variants (28 of which were from the BRIDGES cohort)
were identified by minigene assays. We show that minigene-based mapping of ESEs is a powerful
approach for identifying ESE hotspots and ESE-disrupting variants. Finally, we have classified nine
variants as likely pathogenic according to ACMG/AMP-based guidelines, highlighting the complex
relationship between splicing alterations and variant interpretation.
Keywords: breast cancer; ovarian cancer; susceptibility genes; RAD51D; ESE; ESS; aberrant splicing;
VUS; minigene; clinical interpretation
1. Introduction
RAD51D [MIM#602954] is one of the five RAD51 paralogs (RAD51B, RAD51C, RAD51D,
XRCC2, XRCC3) that play an important role in the repair of DNA double-strand breaks via
homologous recombination [1,2]. RAD51D loss-of-function variants confer risk of breast
and/or ovarian cancer [3,4]. In a cohort of 6690 families, RAD51D pathogenic variants
were associated with relative risks of 7.6 and 1.83 for tubo-ovarian cancer and breast cancer,
respectively [3]. Recently, two large-scale studies have estimated an overall breast cancer
relative risk of 1.8 and 1.72, respectively [5,6]. The association with triple-negative (TN)
breast cancer (RR = 6.1) appears to be particularly strong [5].
During RNA splicing, introns from eukaryotic genes are removed from pre-mRNA,
and consecutive exons are precisely joined together to form mature mRNA [7]. Exon
recognition is a crucial step controlled by a large number of trans-acting factors, including
ribonucleoproteins and splicing factors as well as cis-acting sequences identified by splicing
machinery. The array of splicing signals is extensive and includes 5′ and 3′ splice sites,
the polypyrimidine tract, the branch point and exonic and intronic splicing enhancers
(ESE/ISE) and silencers (ESS/ISS) that stimulate or repress exon inclusion in mature
mRNA [8]. It has been proposed that ~60% of disease-causing variants disrupt pre-mRNA
processing [9], generating aberrant transcripts that can affect protein function and correlate
with an increased risk of a given genetic disease. Consequently, it is imperative to assess
the biological and clinical significance of spliceogenic variants in order to improve genetic
diagnosis and counseling as well as to trigger new therapeutic interventions [10]. Unfortu-
nately, the lack of accurate in silico predictors makes functional assays vital to doing so.
Next, splicing functional assays, either from patient or minigene RNAs, provide critical
data to evaluate the pathogenicity of a particular genetic variant [11–15].
Our study was conducted using the framework of the BRIDGES project (Breast Cancer
After Diagnostic Gene Sequencing; https://bridges-research.eu/, accessed on 1 April 2021),
which has sequenced a panel of 34 known or suspected breast cancer susceptibility genes
in 60,466 cases and 53,461 controls [5]. We bioinformatically analyzed 47 RAD51D variants
from the intron/exon boundaries, 11 of which were selected and functionally tested in a
RAD51D-splicing reporter minigene including exons 2–9 (mgR51D_ex2-9). In addition,
we functionally mapped ESE-rich regions of the non-constitutive exon 3 by overlapping
microdeletions and analyzed 42 candidate BRIDGES and artificial ESE variants. Finally,
we made a tentative clinical classification of BRIDGES variants according to ACMG/AMP
(American College of Medical Genetics and Genomics and the Association for Molecular
Pathology)-based guidelines.
2. Materials and Methods
Ethical approval for this study was obtained from the Ethics Committee of the Spanish
National Research Council-CSIC (28 May 2018).
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2.1. Variant and Transcript Annotations
Forty-seven variants from the intron–exon boundaries (3′ splice-site: intron/exon
[IVS-10_IVS-1/2nt]; 5′ splice-site: exon/intron [2nt/IVS+1_IVS+10]) [16] and 34 from
RAD51D exon 3 were collected from the BRIDGES sequencing data [5]. RNA outcomes
and predicted protein products were described according to the Human Genome Variation
Society guidelines (http://varnomen.hgvs.org/, accessed on 1 April 2021) using Ensembl
reference transcript ID ENST00000345365.10 (GenBank NM_002878.3). To simplify, we also
annotated splicing events, as previously described [17].
2.2. Bioinformatics
The workflow of the splicing assays is outlined in Figure S1. To identify poten-
tial splicing variants, in silico studies were performed using MaxEntScan (MES, http:
//hollywood.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html, accessed on 1 April
2021) (cut-off ≥ 3.0) [18] and NNSplice (https://www.fruitfly.org/seq_tools/splice.html,
accessed on 1 April 2021) [19] when MES was not informative. Potential spliceogenic vari-
ants were selected according to the following criteria: (i) MES score changes (>15%) [16,20]
and (ii) creation of alternative sites (Table S2).
Four in silico approaches were used to predict variant-induced modifications in
splicing regulatory elements: (a) HEXplorer (∆HZEI; cut-off < −5) (https://www2.hhu.
de/rna/html/hexplorer_score.php, accessed on 1 April 2021) [21]; (b) Hot-Skip (https:
//hot-skip.img.cas.cz/, cut-off ≥ 1, accessed on 1 April 2021) or Ex-Skip (https://ex-skip.
img.cas.cz/, accessed on 1 April 2021) [22]; (c) calculation of total ESRseq score changes
(∆tESRseq) by quantitative assessment of RNA hexamers (cut-off < −0.75) [23]; and (d)
alteration of the ESE/ESS balance by HSF at Genomnis (https://hsf.genomnis.com/home,
accessed on 1 April 2021).
2.3. Minigene Construction and Site-Directed Mutagenesis
A 3591-bp fragment including RAD51D exons 2 to 9 and flanking introns was gener-
ated by DNA synthesis (Genewiz, South Plainfield, NJ, USA). This insert was cloned into
the splicing plasmid pSAD [24–26] (minigene mgR51D_ex2-9, Figure 1, Figure S2). All se-
quence variations were introduced into mgR51D_ex2-9 by site-directed mutagenesis using
the QuikChange Lightning kit (Agilent, Santa Clara, CA, USA) (Table S1). All constructs
were confirmed by Sanger sequencing (Macrogen, Madrid, Spain).
2.4. Functional Assays
MCF-7 cell growth, transfection and inhibition of the nonsense-mediated decay were
performed as previously described [16]. The triple-negative breast cancer (TNBC) cell line
MDA-MB-231 was cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented
with 10% fetal bovine serum, 2 mM glutamine, 1% non-essential amino acids and 1%
penicillin/streptomycin solution.
RNA was purified using the Genematrix Universal RNA Purification Kit (EURx,
Gdansk, Poland), with on-column DNAse I digestion. RNA (400 ng) was retrotranscribed
using the vector exon V2-specific primer RTPSPL3-RV (5′-TGAGGAGTGAATTGGTCGAA-
3′) and the RevertAid First-Strand cDNA Synthesis Kit (Life Technologies, Carlsbad, CA,
USA), following the manufacturer’s instructions. Two µL of cDNA were used for am-
plification of the regions of interest using Platinum Taq polymerase (Life Technologies).
To increase specificity, cDNA was amplified, with one primer located in one RAD51C
exon of the insert and another one in a vector exon (V1 or V2). Thus, for variants of the
donor site of exon 2, the amplification was performed using primers SD6-PSPL3_RTFW (5′-
TCACCTGGACAACCTCAAAG-3′) and RTR51D_9-rv (5′-GTCCCTGTCTCGAGTTATG-3′)
(amplicon size = 843 bp). For the remaining variants (exons 3 to 8), the following primers
were used: RTR51D_ex2-fw (5′-TAGCTCAGAAATGTGGCTT-3′) and RTpSAD-RV (Patent
P201231427, CSIC) (size = 885 bp). Samples were denatured at 94 ◦C for 2 min, followed
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by 35 cycles × (94 ◦C, 30 s/59 ◦C, 30 s/72 ◦C, 1 min/kb) and 72 ◦C for 5 min. RT-PCR
products were sequenced by Macrogen (Madrid, Spain).




Figure 1. Structure of the minigene mgR51D_ex2-9 and functional assays of splice-site RAD51D variants. (A) Schematic 
representation of the RAD51D minigene, with exons 2 to 9. (B) Map of variants. (C) Fluorescent fragment analysis of 
transcripts generated by the wild type and mutant minigenes. FAM-labeled products (blue peaks) were run with LIZ-1200 
(orange peaks) as size standard. FL: full-length transcript. 
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performed as previously described [16]. The triple-negative breast cancer (TNBC) cell line 
MDA-MB-231 was cultured in Dulbecco's Modified Eagle Medium (DMEM) supple-
mented with 10% fetal bovine serum, 2 mM glutamine, 1% non-essential amino acids and 
1% penicillin/streptomycin solution. 
RNA was purified using the Genematrix Universal RNA Purification Kit (EURx, 
Gdansk, Poland), with on-column DNAse I digestion. RNA (400 ng) was retrotranscribed 
using the vector exon V2-specific primer RTPSPL3-RV (5′-TGAGGAGTGAATT-
GGTCGAA-3′) and the RevertAid First-Strand cDNA Synthesis Kit (Life Technologies, 
Carlsbad, CA, USA), following the manufacturer’s instructions. Two μL of cDNA were 
Figure 1. Structure of the minigene mgR51D_ex2-9 and functional assays of splice-site RAD51D variants. (A) Schematic
representation of the RAD51D minigene, with exons 2 to 9. (B) Map of variants. (C) Fluorescent fragment analysis of
transcripts generated by the wild type and mutant minigenes. FAM-labeled products (blue peaks) were run with LIZ-1200
(orange peaks) as size standard. FL: full-length transcript.
To estimate the relative proportions of each transcript, semi-quantitative fluorescent
RT-PCRs were performed using a FAM-labeled primer under standard conditions, except
that 26 cycles were herein applied [14,27,28]. Fluorescent products were run with LIZ-1200
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Size Standard by Macrogen (Seoul, Korea) and analyzed using Peak Scanner software
V1.0 (Life Technologies). The mean peak areas of three independent experiments of each
variant were used to calculate the relative proportions of each transcript as well as the
standard deviations.
2.5. ACMG/AMP-Like Classification of 37 RAD51D Variants Detected in BRIDGES Samples
No RAD51D expert panel specifications of the American College of Medical Genetics
and Genomics or the Association for Molecular Pathology (ACMG/AMP) variant curation
guidelines were currently available (www.clinicalgenome.org, last accessed on 29 December
2020). Therefore, we performed a tentative classification based on: (i) generic ACMG/AMP
guidelines [29], (ii) specific recommendations of the ClinGen Sequence Variant Interpreta-
tion Working Group for interpreting the loss-of-function PVS1 [30] and functional PS3/BS3
evidence codes [31], (iii) some non-gene-specific approaches proposed by the ClinGen
CDH1 variant curation expert panel [32] and (iv) ad hoc rules based on expert judgment.
The latter were essential to assign a specific functional splicing code (PS3/BS3) to complex
minigene readouts (Supplementary Methods). In addition to PS3/BS3, only the rarity code
(PM2) made a significant contribution to the classification process.
3. Results
3.1. Bioinformatics Analysis and Functional Assays
Forty-seven RAD51D variants detected in BRIDGES subjects were collected from the
intron–exon boundaries of exons 2 to 9 and analyzed using MaxEntScan (MES) or NNSplice
(Table S2). Eleven potential splice-site disrupting variants were selected to be assayed in
MCF-7 cells (Table 1).
A RAD51D minigene with exons 2–9 was constructed in splicing vector pSAD (mini-
gene mgR51D_ex2–9, Figures 1 and S2). Fragment analysis of the wild type (wt) minigene
revealed the full-length (FL) transcript (V1-RAD51D exons 2 to 9-V2) and several alternative
isoforms (Table 1; Figure 1C), of which ∆(E2_5), ∆(E3_5) and ∆(E4_5), among others, were
formerly reported as naturally occurring transcripts [33]. All 11 variants impaired splicing,
wherein the FL transcript was (almost) absent in 10 variants and c.263+6T>C still expressed
a considerable level of FL transcript (49%). Eight of these variants (c.263+6T>C, c.343C>T,
c.345+2T>C, c.480+1G>A, c.476_480+1dup, c.481-8C>A, c.577-2A>G and c.738+1G>A)
were also tested in the triple-negative breast cancer cells MDA-MB-231, in which they
replicated the splicing profiles (Figure S3).
Five variants disrupted the canonical 3′ splice site (3′SS), although c.83-4_83-3delinsAG
and c.481-8C>A also created a de novo site (transcripts (E2p2) and H(E6p6), respec-
tively), and variant c.577-2A>G mainly provoked the use of an intronic cryptic 3′SS
(H(E7p41)). Four variants disrupted the canonical 5′ splice site (5′SS): c.345+2T>C,
c.480+1G>A, c.476_480+1dup and c.738+1G>A. Variants c.476_480+1dup and c.738+1G>A
also caused the recognition of alternative 5’SS (H(E5q6) and H(E8q43), respectively). Fi-
nally, c.263+6T>C and c.343C>T weakened the natural 5′SS of exons 3 and 4, respectively.
3.2. Transcript Analysis
Our minigene analysis identified 25 transcripts, including the alternative ones gener-
ated by the wt minigene (Table S3 and Figure S4). Exon (or multi-exon) skipping was a
frequent outcome, with 13 different aberrant transcripts detected: ∆(E2), ∆(E2_3), ∆(E2_5),
∆(E3), ∆(E3_5), ∆(E3_7), ∆(E4), ∆(E4_5), ∆(E4_7), ∆(E5), ∆(E6_9), ∆(E7) and ∆(E8). Another
five aberrant transcripts were due to the use of de novo splice sites (H(E2p2), H(E5q6),
H(E6p6), H(E7p41) and H(E8q43)), and five aberrant transcripts combined skipping and
alternative site usage events ((∆(E2) H(E5q6)), (∆(E3) H(E5q6)), (∆(E3_5) H(E6p6)), (∆(E4)
H(E5q6)) and (∆(E4_5) H(E6p6)). Two additional fragments of 487- and 1363-nt were also
found, but the presumed aberrant events could not be characterized. Seventeen transcripts
introduced PTCs that were predicted to inactivate RAD51D, and six kept the reading frame
(Table 1, Supplementary Methods).
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Table 1. Bioinformatics analysis and splicing outcomes of RAD51D canonical splice variants.
Variant (HGVS) 1 Bioinformatics (MaxEnt Scan) 2
Transcripts 3
Canonical PTC In-Frame Uncharacterized
mgR51D_ex2-9 Primers V1-ex9
Wild type - 57.8% ± 5.6
∆(E4_5) (13.8% ± 1.3);
∆(E3_7) (9.9% ± 2.6);
∆(E2_5) (5.2% ± 0.8)
∆(E3_5) (13.3% ± 2.4) -
c.83-2A>G [−] 3′SS (8.52→0.56) -
∆(E2_5) (41.9% ± 1.1);
∆(E2) (39.6% ± 0.9);
∆(E2_3) (9.6% ± 0.1)
- 487-nt (9.0% ± 0.2)
c.83-4_83-3delinsAG [−] 3
′SS
[+] 3′SS (5.42) 2-nt upstream -
H(E2p2) (54.2% ± 2.0);
∆(E2_5) (38.6% ± 2.1);
∆(E2) (7.2% ± 0.4)
- -
mgR51D_ex2-9 Primers ex2-V2 - -
Wild type 73.1% ± 5.6 ∆(E4_5) (9.4% ± 3) ∆(E3_5) (17.5% ± 5.2) -
c.145-2A>G [−] 3′SS (2.43) - ∆(E3) (55.5% ± 0.6) ∆(E3_5) (44.5% ± 0.6) -
c.263+6T>C 5′SS: 7.44→4.86 49.0% ± 1.2 ∆(E3) (15.6% ± 0.3) ∆(E3_5) (35.4% ± 1.2) -
c.343C>T 5′SS: 7.79→4.36 3.4% ± 0.7 ∆(E4) (45.7% ± 1.0);∆(E4_5) (28.1% ± 0.6) ∆(E3_5) (22.7% ± 1.2) -
c.345+2T>C [−] 5′SS (7.79→0.04) - ∆(E4) (49.6% ± 1.4);∆(E4_5) (26.4% ± 1.0) ∆(E3_5) (24.0% ± 0.7) -
c.480+1G>A [−] 5′SS (11.08→2.9) - ∆(E4_5) (29.2% ± 0.4) ∆(E3_5) (41.2% ± 0.7);∆(E5) (29.6% ± 0.4) -
c.476_480+1dup [−] 5′SS (11.08→0.5) -
∆(E4_5) (8.6% ± 0.4);
(∆(E4) H(E5q6)) (6.3% ± 0.1);
(∆(E2) H(E5q6)) (4.3% ± 0.1);
(∆(E3) H(E5q6)) (3.6% ± 0.4)
H(E5q6) (60.4% ± 4.3);
∆(E3_5) (16.7% ± 5.0) -
c.481-8C>A 3
′SS: 8.21→1.75
[+] 3′SS (11.06) 6-nt upstream 0.4% ± 0.1 (∆(E4_5) H(E6p6)) (13.4% ± 0.2)
H(E6p6) (70.0% ± 0.8); (∆(E3_5)
H(E6p6)) (8.8% ± 0.3);
∆(E3_5) (7.5% ± 0.3)
-
c.577-2A>G [−] 3′SS (10.36→2.41) - H(E7p41) (65.5% ± 0.5);∆(E7) (14.3% ± 0.2) ∆(E6_9) (20.2% ± 0.8) -
c.738+1G>A 4 [−] 5′SS (6.13→−2.05) -
H(E8q43) (27.9% ± 0.1);
∆(E8) (51.1% ± 0.2);
∆(E4_7) (10.9% ± 0.1)
- 1363-nt (10.1% ± 0.0)
1 Variants without full-length transcripts or residual amounts (<5%) are indicated in bold font. 2 [−]: site disruption; [+]: new site. 3 Transcripts are described with a combination of the following symbols:
H (incorporation of intronic sequences that were not present in the reference transcript), ∆ (skipping of exonic sequences that were present in the reference transcript), E (exon), p (new acceptor site), q (new donor
site) and a number representing the exact number of nucleotides incorporated or skipped. For example, H(E2p2) denotes the use of an alternative acceptor site 2 nucleotides upstream of exon 2, causing the
addition of 2-nt to the mature mRNA. 4 According to reference [33], c.738+1G>A causes only a 37-nucleotide intron retention H(E8q37). Yet, some methodological issues (location of PCR primers not reported,
RT-PCR products analyzed only by low-sensitivity agarose electrophoresis, no agarose band isolation before Sanger sequencing and no allele-specific information) precluded, in our opinion, direct comparison
with our minigene results.
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3.3. ESE Mapping
Effective exon recognition in alternative splicing requires the binding of trans-acting
factors to exon-splicing enhancer (ESE) sequences [34]. Exon 3 is a non-constitutive exon,
excluded from several RAD51D naturally occurring, alternatively spliced isoforms [33]
and consequently, it is likely regulated by splicing regulatory elements (SRE) [35]. We
proceeded to functionally map SREs in exon 3 by introducing four overlapping 30–35-bp
deletions (c.147_176del, c.172_206del, c.202_235del and c.231_260del) along this exon (119
bp), excluding the first two and last three nucleotides to preserve splice site-conserved
positions [24,25]. All four deletions had an impact on splicing, and different levels of
exon 3 skipping were observed (Figure 2A,B; Table S4; Figure S5), pointing out that these
sequences might have contained regulatory motifs. Deletion c.202_235del affected splicing
the most, observing no trace of the FL transcript (Figure 2A,B).
We then decided to functionally assay 25 BRIDGES variants reported at the most
spliceogenic segment, c.202_235del, and surrounding sequences. In this study, variants
with a FL transcript proportion ranging from 65.8 to 73.1% (<10% reduction of the FL
transcript in the wt minigene) were not considered spliceogenic (see Section 4). In total,
16 out of 25 variants (64%) effectively disrupted splicing (Table 2; Figures 2A,B and S5),
wherein exon 3 skipping (not observed in the wt minigene) was detected and ∆(E3_5) was
increased (>17.5%) in all the spliceogenic variants. In addition, c.202G>A also expressed a
new isoform, ∆(E3p36), through the use of an internal cryptic acceptor site. Remarkably,
c.202G>A was the only variant that did not produce FL transcripts, whereas c.214T>C
produced 100% full-length transcripts.
To refine the SRE map and identify potential hotspots for spliceogenic variants, five
additional overlapping 10/11-bp deletions of the c.202_235 interval were tested. All
deletions impaired splicing, being particularly significant in c.210_219del, wherein the FL
transcript was absent (Table S4, Figure S5). Next, we tested all the possible changes of
the highest spliceogenic interval, c.210_219. We selected the six specific nucleotides, i.e.,
c.212–217, within this segment that were not shared with the overlapping microdeletions
c.202_211del and c.218_227del (see Figure 2A). BRIDGES variants c.213C>T, c.214T>C,
c.216C>T and c.217G>A of this segment had been already tested in the preliminary SRE
assays (Table 2). Next, the 14 remaining possible nucleotide substitutions in segment c.212–
c.217 were introduced into the minigene and evaluated. They represented the so-called
“artificial” (ad hoc) variants that had not been identified in BRIDGES subjects. Eleven
artificial variants within this interval impaired splicing, reducing the FL transcript by
≥10%, inducing the aberrant transcript ∆(E3) and increasing the relative proportion of
the alternative isoform ∆(E3_5). Putting together the artificial and BRIDGES variants of
c.212–217, the final proportion of spliceogenic variants was 66.7% (12/18).
In order to assess the accuracy of four ESE/ESS prediction tools (Human Splicing
Finder (HSF), HEXplorer, Hot-Skip and ∆tESRseq), we pooled together and analyzed the
25 BRIDGES variants and the 14 artificial ones of the c.212–217 segment (Table 2; Tables
S5 and S6) [36,37]. HEXplorer showed the highest sensitivity (74.1%, 20/27) and accuracy
(61.5%) but also showed the lowest specificity (33.3%). The sensitivity of the other three
predictors was very low (<37%). On the other hand, Hot-Skip presented the highest
specificity (83.3%), but also 19 false negative variants. Remarkably, the spliceogenic variant
c.199A>G would not have been predicted by any tool. Moreover, Hot-Skip analysis of the
full exon 3 sequence suggested three changes with the highest probabilities of splicing
disruption: c.163C>T (detected in BRIDGES subjects), c.163C>G and c.178C>T. We tested
them in our RAD51D minigene, where they had weak-to-moderate effects, generating
different quantities of the FL isoform (38.7–62.0%; Table 2).
Summarizing, we evaluated a total of 42 candidate ESE variants (26 identified in
BRIDGES subjects), 30 of which impaired RAD51D exon 3 splicing.
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3.4. ACMG/AMP-Like Classification of 37 RAD51D Variants Identified in the BRIDGES Cohort
We developed ACMG/AMP-based specifications for the interpretation of RAD51D
spliceogenic variants (see Supplementary Methods, Figures S6–S8). With this approach,
based on minigene read-outs (PS3/BS3 codes) and gnomADv2.1 global population fre-
quencies (PM2/BS1/BA1 codes), we classified 37 BRIDGES variants (Table 3). As expected,
most variants located at canonical splice sites (9 of 11) ended up as likely pathogenic. By
contrast, many of the remaining variants ended up as variants of uncertain significance
(VUS), despite demonstrating an effect on splicing.
Figure 2. Analysis of RAD51D exon 3 variants. (A) Map of exon 3 microdeletions and tested variants. Boxes: red, total
splicing disruptions; yellow, weak to moderate disruptions. Spliceogenic variants are shown in red. (B) Fluorescent
fragment analysis of transcripts generated by selected microdeletions (left) and variants (right). FAM-labeled products (blue
peaks) were run with LIZ-1200 (orange peaks) as the size standard.
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Table 2. Bioinformatics analysis and splicing outcomes of putative exon 3 ESE variants.
Variant 1
Transcripts 2 In Silico Tools 3
Canonical PTC In-Frame HSF HEXplorer Hot-Skip ∆tESRseq
Wild type 73.1% ± 5.6 ∆(E4_5) (9.4% ± 3) ∆(E3_5) (17.5% ± 5.2) -
BRIDGES variants
c.171G>A 76.0% ± 1.4 ∆(E4_5) (8.4% ± 0.4) ∆(E3_5) (18.6% ± 1.1) - −40.3 0 −1.03
c.175G>T 52.9% ± 2.6 ∆(E4_5) (9.7% ± 1.1)
∆(E3) (9.6% ± 0.4) ∆(E3_5) (27.7% ± 1.2) - −27.0 2 1.30
c.180G>A 67.5% ± 2.6 ∆(E4_5) (14.4% ± 1.1) ∆(E3_5) (18.1% ± 1.5) - 2.5 0 0.25
c.180G>T 69.4% ± 0.5 ∆(E4_5) (13.7% ± 0.1) ∆(E3_5) (16.9% ± 0.4) - −65.1 5 0.25
c.184T>A 37.2% ± 0.6 ∆(E3) (31.1% ± 1.5) ∆(E3_5) (31.7% ± 1.5) + 23.3 0 −0.67
c.185C>T 66.3% ± 1.2 ∆(E4_5) (9.9% ± 0.5) ∆(E3_5) (23.8% ± 1.5) - −53.9 7 −1.85
c.186G>A 64.3% ± 0.5 ∆(E4_5) (7.4% ± 0.1)
∆(E3) (8.5% ± 0.0) ∆(E3_5) (19.7% ± 0.4) + −23.2 0 −1.88
c.187G>A 59.8% ± 2.9 ∆(E3) (13.9% ± 0.9) ∆(E3_5) (26.3% ± 2.3) + 13.4 0.3 0.65
c.187G>C 27.4% ± 0.4 ∆(E3) (38.3% ± 0.4) ∆(E3_5) (34.2% ± 0.3) - −12.4 1 −0.05
c.195C>T 69.7% ± 0.3 ∆(E4_5) (10.2% ± 0.1) ∆(E3_5) (20.1% ± 0.3) - −22.8 0.4 −0.26
c.196G>A 58.8% ± 1.6 ∆(E4_5) (5.4% ± 0.3)
∆(E3) (10.6% ± 0.8) ∆(E3_5) (33.3% ± 2.1) - −17.2 0 −1.72
c.198G>T 48.7% ± 1.8 ∆(E4_5) (5.9% ± 0.3)
∆(E3) (17.1% ± 0.7) ∆(E3_5) (28.3% ± 0.9) - −47.3 5 −2.69
c.199A>G 65.1% ± 1.0 ∆(E3_5) (34.9% ± 1.0) - 37.8 0.7 1.31
c.200_218del 28.7% ± 0.5 ∆(E3) (46.9% ± 0.0) ∆(E3_5) (24.4% ± 0.5) - −119.8 0.26 −4.14
c.202G>A - ∆(E3) (26.7% ± 0.9) ∆(E3_5) (41.1% ± 3.1);
∆(E3p36) (32.2% ± 2.9) - −38.5 0 −1.58
c.208G>A 46.8% ± 1.1 ∆(E3) (16.8% ± 0.2) ∆(E3_5) (36.4% ± 1.2) + −52.1 0 −1.37
c.209A>T 58.2% ± 1.0 ∆(E4_5) (10.0% ± 0.3)
∆(E3) (9.2% ± 0.2) ∆(E3_5) (22.6% ± 0.9) - −58.0 5 −0.30
c.211C>T 60.6% ± 0.7 ∆(E4_5) (8.6% ± 0.0)
∆(E3) (7.9% ± 0.3) ∆(E3_5) (23.0% ± 0.5) - −63.2 2.5 0.19
c.213C>T 57.2% ± 0.4 ∆(E3) (19.5% ± 0.0) ∆(E3_5) (23.3% ± 0.3) - −53.1 4 −1.55
c.214T>C 100.0% ± 0.0 + 6.7 0 −0.30
c.216C>T 68.4% ± 0.2 ∆(E3) (14.0% ± 0.0) ∆(E3_5) (17.6% ± 0.4) - −34.1 0 −2.38
c.217G>A 66.5% ± 2.0 ∆(E4_5) (12.5% ± 0.3) ∆(E3_5) (21.0% ± 1.7) + −7.8 0 −0.94
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Variant 1
Transcripts 2 In Silico Tools 3
Canonical PTC In-Frame HSF HEXplorer Hot-Skip ∆tESRseq
c.224T>C 59.9% ± 0.9 ∆(E4_5) (13.4% ± 0.1) ∆(E3_5) (26.7% ± 0.8) - −9.3 0 0.27
c.234C>T 70.7% ± 0.5 ∆(E4_5) (11.5% ± 0.2) ∆(E3_5) (17.8% ± 0.4) + −0.3 0 0.10
c.243C>T 50.9% ± 1.2 ∆(E3) (16.8% ± 0.1) ∆(E3_5) (32.3% ± 1.1) - −59.7 4 −0.58
Artificial Variants c.212_217
c.212T>A 63.6% ± 2.3 ∆(E3) (5.5% ± 0.3)∆(E4_5) (5.5% ± 0.0) ∆(E3_5) (25.4% ± 2.6) + 16.1 0 0.51
c.212T>C 62.7% ± 1.0 ∆(E3) (5.5% ± 0.1)∆(E4_5) (7.1% ± 0.0) ∆(E3_5) (24.7% ± 0.9) + −0.4 0 −0.01
c.212T>G 63.4% ± 2.1 ∆(E3) (5.9% ± 0.2)∆(E4_5) (4.9% ± 0.2) ∆(E3_5) (25.8% ± 1.9) + 41.8 0 1.58
c.213C>A 41.4% ± 0.3 ∆(E3) (11.1% ± 0.2)∆(E4_5) (6.4% ± 0.0) ∆(E3_5) (41.1% ± 0.5) - −25.6 0.5 −0.81
c.213C>G 49.6% ± 0.6 ∆(E3) (6.7% ± 0.1)∆(E4_5) (6.1% ± 0.0) ∆(E3_5) (37.6% ± 0.7) - −20.1 0.5 0.57
c.214T>A 64.3% ± 1.3 ∆(E4_5) (10.9% ± 0.1) ∆(E3_5) (24.8% ± 1.3) + 19.1 0 0.87
c.214T>G 65.8% ± 2.4 ∆(E4_5) (11.3% ± 0.3) ∆(E3_5) (18.9% ± 0.4) - 18.3 0 3.41
c.215A>C 28.7% ± 0.2 ∆(E4_5) (9.6% ± 0.3) ∆(E3_5) (61.7% ± 0.4) - −40.5 0 1.82
c.215A>G 69.9% ± 1.6 ∆(E4_5) (9.4% ± 0.2) ∆(E3_5) (20.7% ± 1.5) - −27.9 0.33 1.78
c.215A>T 70.6% ± 1.7 ∆(E4_5) (8.7% ± 0.1) ∆(E3_5) (20.7% ± 1.6) - −21.2 0.67 1.90
c.216C>A 54.7% ± 1.0 ∆(E3) (12.8% ± 0.4) ∆(E3_5) (32.5% ± 1.4) - −73.7 0.13 −0.56
c.216C>G 36.4% ± 0.6 ∆(E3) (22.1% ± 1.3) ∆(E3_5) (41.6% ± 1.9) - −91 0.33 −1.15
c.217G>C 62.7% ± 0.5 ∆(E3) (8.3% ± 0.1) ∆(E3_5) (29.0% ± 0.4) - −21.2 0 −0.27
c.217G>T 63.6% ± 0.4 ∆(E3) (14.3% ± 0.3) ∆(E3_5) (22.1% ± 0.5) - −114.2 1.67 −1.66
Hot-Skip Variants
c.163C>G 38.7% ± 3.0 ∆(E3) (26.9% ± 0.7) ∆(E3_5) (34.4% ± 2.5) - −92.7 18 −2.81
c.163C>T
(BRIDGES) 62.0% ± 0.5
∆(E4_5) (12.3% ± 0.3)
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Table 2. Cont.
Variant 1
Transcripts 2 In Silico Tools 3
Canonical PTC In-Frame HSF HEXplorer Hot-Skip ∆tESRseq
c.178C>T 54.3% ± 1.0 ∆(E3) (16.0% ± 0.1);∆(E4_5) (4.8% ± 0.1) ∆(E3_5) (24.9% ± 0.8) - −44.7 12 −2.08
1 Spliceogenic variants are indicated in bold type. 2 Remarkable transcript variations are indicated in bold type: ≥10% reduction of the canonical transcript, detection of the anomalous ∆(E3) or increase of the
∆(E3_5) isoform higher than 22.7% (mean + s.d. of ∆(E3_5) in the wt minigene). 3 Bold font: HSF, alteration of the ESE/ESS motifs ratio [+]; scores of HEXplorer, Hot-Skip and ∆tESRseq below or above their
corresponding cutoffs (≤−5, ≥1 and ≤−0.75, respectively).
Table 3. Proposed pSAD-based ACMG/AMP clinical classification of 37 RAD51D genetic variants detected in the BRIDGES cohort.
c.HGVS 1 p.HGVS 1 Clinvar 2 PS3/BS3 3 PM2/BS1/BA1 4 Proxy for Allele Counts 5 Variant Classification 6
c.83-4_-3delinsAG p.? VUS (**) PS3_VS (0/251433) PM2 rs780590372 (=) Likely Pathogenic (PS3_VS + PM2)
c.83-2A>G p.? LP (*) PS3_VS (91%PS3_VS + 9%N/A) 7 (0/251433) PM2 rs780590372 (−1) Likely Pathogenic (PS3_VS + PM2)
c.145-2A>G p.? not reported PS3_VS (0/251102) PM2 rs201974522 (−1) Likely Pathogenic (PS3_VS + PM2)
c.163C>T p.(Arg55Trp) VUS (**) N/A (62%N/A + 38%PS3_VS) (2/251433) PM2 - Uncertain Significance (PM2 only) 8
c.171G>A p.(Leu57=) LB (**) BS3 (76%BS3 + 24%PS3_VS) (0/249480) PM2 rs745307359 (−4) Uncertain Significance (BS3 + PM2)
c.175G>T p.(Ala59Ser) not reported N/A (53%N/A + 47%PS·_VS) (0/251298) PM2 rs780689600 (+4) Uncertain Significance (PM2 only) 8
c.180G>A p.(Gln60=) LB (*) BS3 (68%BS3 + 32%PS3_VS) (0/251298) PM2
rs780689600 (−1)
Uncertain Significance (BS3 + PM2)
c.180G>T p.(Gln60His) VUS (**) N/A (69%N/A + 31%PS3_VS) (0/251298) PM2 Uncertain Significance (PM2 only) 8
c.184T>A p.(Ser62Thr) not reported N/A (37%N/A + 63%PS3_VS) (0/251382) PM2 rs374357106 (+3) Uncertain Significance (PM2 only) 8
c.185C>T p.(Ser62Leu) VUS (**) N/A (66%N/A + 34%PS3_VS) (5/251382) N/A - Uncertain Significance (no codes) 8
c.186G>A p.(Ser62=) LB (**) N/A (64%BS3 + 36%PS3_VS) (3/251380) N/A - Uncertain Significance (no codes) 8
c.187G>A p.(Ala63Thr) VUS (**) N/A (60%N/A + 40%PS3_VS) (1/251408) PM2 - Uncertain Significance (PM2 only) 8
c.187G>C p.(Ala63Pro) not reported N/A (27%N/A + 73%PS3_VS) (0/251408) PM2 c.187G>A Uncertain Significance (PM2 only) 8
c.195C>T p.(Pro65=) LB (**) BS3 (70%BS3 + 30%PS3_VS) (5/251420) N/A - Uncertain Significance (BS3 only)
c.196G>A p.(Val66Met) B (2), LB (4), VUS (4) N/A (59%N/A + 41%PS3_VS) (80/251384) BS1 - Uncertain Significance (BS1) 8
c.198G>T p.(Val66=) LB (**) N/A (49%BS3 + 51%PS3_VS) (9/251448) N/A - Uncertain Significance (no codes) 8
c.199A>G p.(Asn67Asp) not reported N/A (65%N/A + 35%PS3_VS) (0/251448) PM2 rs546461804 (+1) Uncertain Significance (PM2 only) 8
c.200_218del p.(Asn67Argfs*7) not reported PS3_VS (0/251448) PM2 rs54661804 (=) Likely Pathogenic (PS3_VS + PM2)
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Table 3. Cont.
c.HGVS 1 p.HGVS 1 Clinvar 2 PS3/BS3 3 PM2/BS1/BA1 4 Proxy for Allele Counts 5 Variant Classification 6
c.202G>A p.(Gly68Ser) VUS (**) PS3 (68%PS3_VS + 32%PS3) (9/251454) N/A - Uncertain Significance (PS3 only)
c.208G>A p.(Asp70Asn) VUS (**) N/A (47%N/A + 53%PS3_VS) (8/251458) N/A - Uncertain Significance (no codes) 8
c.209A>T p.(Asp70Val) VUS (**) N/A (58%N/A + 42%PS3_VS) (1/251450) PM2 - Uncertain Significance (PM2 only) 8
c.211C>T p.(Leu71Phe) VUS (*) N/A (61%N/A + 39%PS3_VS) (0/251476) PM2 rs559850711 (+1) Uncertain Significance (PM2 only) 8
c.213C>T p.(Leu71=) LB (**) N/A (57%BS3 + 43%PS3_VS) (2/251466) PM2 - Uncertain Significance (PM2 only) 8
c.214T>C p.(Tyr72His) not reported N/A (0/251466) PM2 rs745546403 (−1) Uncertain Significance (PM2 only)
c.216C>T p.(Tyr72=) B/LB (**) BS3 (67%BS3 + 33%PS3_VS) (27/251474) N/A - Uncertain Significance (BS3)
c.217G>A p.(Glu73Lys) VUS (**) N/A (67%N/A + 33%PS3_VS) (2/251462) PM2 - Uncertain Significance (PM2 only) 8
c.224T>C p.(Leu75Pro) not reported N/A (60%N/A + 40%PS3_VS) (0/251466) PM2 rs746929682 (−1) Uncertain Significance (PM2 only) 8
c.234C>T p.(Ser78=) B (**) BS3 (71%BS3 + 29%PS3_VS) (29273/251448) BA1 - Benign (BS3 + BA1)
c.243C>T p.(Ile81=) LB (**) N/A (60%BS3 + 40%PS3_VS) (1/251472) PM2 - Uncertain Significance (PM2 only) 8
c.263 + 6T>C p.? not reported N/A (49%BS3 + 51%PS3_VS) (0/251424) PM2 rs56218020 (+1) Uncertain Significance (PM2) 8
c.343C>T p.(Gln115Ter) P (**) PS3_VS (0/141295) PM2 rs786202507(−4)rs878854562(+7) Likely Pathogenic (PS3_VS + PM2)
c.345+2T>C p.? LP(1); VUS(1) PS3_VS (0/251220) PM2 rs878854562 (+3) Likely Pathogenic (PS3_VS + PM2)
c.476_480+1dup p.? not reported N/A (40%PS3_VS + 60%N/A) (0/251474) PM2 rs1057521922 (=) Uncertain Significance (PM2 only) 8
c.480+1G>A p.? (-) PS3 (70%PS3_VS + 30%PS3) (0/251474) PM2 rs1057521922 (−3) Likely Pathogenic (PS3 + PM2)
c.481-8C>A p.? not reported N/A (30%PS3_VS + 70%N/A) (0/241990) PM2 rs762247126 (=) Uncertain Significance (PM2 only) 8
c.577-2A>G p.? P/LP (**) PS3 (80%PS3_VS + 20%PS3) (0/250980) PM2 rs1210749655 (−4) Likely Pathogenic (PS3 + PM2)
c.738+1G>A p.? LP (**) PS3_VS (70%PS3_VS +10%N/A) 7 (0/240992) PM2 rs1210620444 (−1) Likely Pathogenic (PS3 + PM2)
9
1 NM_002878.3. 2 ClinVar last accessed 10 May 2021. VUS: variant of uncertain significance, LP: likely pathogenic, P: pathogenic, LB: likely benign, B: benign. Criteria provided + multiple submitters + no
conflicts (**), criteria provided + single submitter (*), no assertion criteria provided (-). If interpretations conflict, the number of submitters supporting each interpretation is indicated. 3 pSAD read-outs
were deconvoluted into individual transcripts that were interpreted as per ClinGen-SVI PVS1 decision tree recommendations; very strong pathogenic: PS3_VS; strong pathogenic: PS3; strong benign: BS3;
BA1: stand-alone benign, allele frequency >5%; N/A: no code strengths applicable. If transcripts with different evidence strengths were observed, the approximated contribution to the overall expression is
shown (%). Combined PS3 strength was based on expert judgment (see Section 2). 4 For rarity evidence, we counted alleles in gnomADv2.1 global. 5 If absent from gnomADv2.1 global, counted alleles were
inferred using the nearest reference SNP as a proxy (−/+, upstream/downstream distance, = overlapping). 6 Not intended as a definitive clinical classification (see Section 4). 7 Both variants expressed a
non-negligible proportion of transcripts not fully characterized (see Table 1 and Supplementary Methods). 8 Candidate intermediate risk variants (see Section 4). 9 Despite its differences, both the current study
and references [38] support a likely pathogenic classification for this variant.
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4. Discussion
The progress in DNA sequencing technology has resulted in the development of
multi-gene panels for clinical genetic testing of diverse genetic diseases, including hered-
itary breast cancer. Although next-generation sequencing is a powerful tool to identify
potentially deleterious variants, most variants are classified as VUS because there are no
existing datasets correlating them with their impact on gene function and cancer risk [39].
The goal of the BRIDGES initiative was to establish reliable breast cancer risk estimates for
34 putative breast cancer susceptibility genes commonly included in multigene panels by
sequencing more than 60,000 breast cancer cases and 53,000 controls [5]. As a partner in this
project, we have carried out the most comprehensive functional evaluation of candidate
splice variants of RAD51D performed so far.
Despite the fact that assays using patient-derived RNA are considered the most
suitable strategy to evaluate splicing outcomes, minigene assays have proved to be a useful,
simple and robust approach to assess potential spliceogenic variants [12,40]. This method
presents several significant advantages such as (1) analysis of single allele events without
the meddling of the WT allele; (2) accurate quantification of isoforms by inhibiting the
nonsense-mediated decay; (3) high versatility, allowing the study of different variants
with a single minigene; (4) high reproducibility of physiological and pathological splicing
patterns; (5) analysis in a cell type relevant for the disease.
In relation to the latter, we have performed all analyses in breast cancer cell line
MCF-7, and we have performed a sub-analysis in the TN breast cancer cell line MDA-
MB-231, replicating findings (Figure S3). Current data supports a shared heritability for
ER-negative (or TN) breast cancer and ovarian cancer susceptibility [3,41–43]. Interestingly,
epidemiological and molecular evidence indicates that high-grade serous ovarian cancer
arises not from ovarian epithelial cells, but from cells in the fimbriae of the fallopian
tubes [44]. At any rate, the RAD51D alternative splicing profiles in fimbria, ovary and
breast samples are similar [33], lending further support to the relevance of our analyses.
As indicated, we have performed all experiments in malignant breast epithelial cell lines,
despite the fact that the carcinogenic process may target the splicing machinery [45]. Yet,
in a previous study, non-malignant cells (MCF-10A) demonstrated clear disadvantages
such as very slow growth and high cell lethality after transfection [46]. Further, in the same
study, we observed similar minigene splicing outcomes in malignant and non-malignant
cell lines.
Many studies, including previous work by our group, support the ability of mini-
gene assays to accurately reproduce splicing alterations as observed in RNA from car-
riers [16,24,25,47–49]. Unfortunately, as far as we know, none of the RAD51D variants
here assessed have been tested previously in RNA from carriers (the only exception being
a sub-optimal study performed in a c.738+1G>A carrier, see footnote to Table 1). Yet,
our RAD51D minigene (Figure 1) mimicked several physiological alternative splicing
events [33], supporting the accuracy of the approach. Of note, splicing assays performed
in RNA from carriers do not necessarily provide an accurate description of the actual
spliceogenic effects caused by a genetic variant, as conflicting data in carriers of the same
variant do exist (e.g., BRCA2 c.7976+5G>T or PALB2 c.3113+5G>C) [17,50–52]. In brief,
caution should be taken when interpreting the biological and clinical implications of any
splicing assay, irrespective of the experimental approach. Bearing this in mind, minigenes
are certainly valuable tools for initial risk assessment, particularly if RNAs from carriers
are not available.
In summary, we tested 53 RAD51D variants (37 from BRIDGES subjects and 16 artificial
variants) in the RAD51D minigene: 11 splice-site and 42 putative, SRE-disrupting variants.
Forty-one of them (77.4%; 11 splice-site and 30 ESE/ESS variants) impaired normal splicing
patterns, supporting the high frequency of this deleterious mechanism.
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4.1. Splice-Site Variants
Historically, a splice variant was considered critical when it affected positions ±1, 2,
but other nucleotides are crucial for exon recognition, as well. Here, we analyzed 11 changes
of the intron/exon boundaries, comprising seven ± 1, 2 variants, as well as other changes
at intron positions−3,−4,−8 and +6 and the antepenultimate exon nucleotide. Our results
showed that 10 variants dramatically disrupted splicing because they showed no trace, or
residual amounts, of the FL transcript. Five variants disrupted the 3’SS, and remarkably,
three of them induced the use of de novo or cryptic acceptor sites. Six variants disrupted
or weakened the 5′SS wherein exon skipping was the main outcome, although two of them
also provoked the use of alternative donors. Only variant c.263+6T>C showed a significant
proportion of the FL transcript (49%). Finally, it is worthy of mention that MES correctly
anticipated disruptions of the canonical splice sites.
4.2. SRE-Spliceogenic Variants
Alternative splicing is a major mechanism for increasing gene expression complexity,
producing multiple mRNA and protein isoforms, and is regulated by a huge array of
factors [53]. RAD51D exon 3 is a non-constitutive exon [33], so it is conceivable that it
is controlled by ESE/ESS elements [54]. Given the low accuracy of ESE/ESS predictors,
we mapped exon 3 by overlapping exonic microdeletions. This approach revealed the
existence of ESE motifs throughout this exon because all the microdeletions influenced exon
3 recognition, being particularly significant at interval c.202_235. This result confirmed
that this region was characterized by a high density of cis-regulatory motifs that controlled
exon 3 inclusion. Fine mapping using internal 10/12-bp deletions showed that interval
c.210_219 was crucial in exon 3 recognition because its deletion strongly triggered exon
skipping and did not show any trace of FL transcript. Consequently, potential spliceogenic
ESE variants might have appeared in these ESE-rich segments. Altogether, we tested
42 potential ESE/ESS variants mapping to these ESE-rich intervals. Of note, in a region
with high levels of naturally occurring alternative splicing and most variants having
limited impacts, the definition of a spliceogenic variant is controversial. In this study,
we defined an arbitrary 10% reduction cutoff for the contribution of the FL transcript
to the overall expression (i.e., variants with 65.8% to 73.1% of the FL transcript were not
considered spliceogenic). Based on this cut-off criteria, 30 variants (71.4%; Table 2) impaired
splicing, thus supporting our SRE-screening strategy. All spliceogenic SRE-variants but
one (c.202G>A) produced non-negligible levels of FL transcripts (65.1% to 27.4%), with
variants c.216C>G, c.215A>C, c.200_218del and c.187G>C producing 36.4%, 28.7%, 28.7%
and 27.4%, respectively. c.202G>A was the only tested SRE variant that did not generate
FL transcripts. Curiously, c.214T>C presented the opposite effect, strengthening exon
3 inclusion to produce only FL transcripts.
The partial impact of these variants might have been due to the disruption of inde-
pendent active ESEs, which, in physiological conditions, might synergistically cooperate
for efficient exon recognition, as previously reported [27]. In effect, some deletions such
as c.202_235del and c.200_219del (Table S4), which remove the crucial c.212_217 hotspot,
display strong effects (no trace of the FL transcript) because they would simultaneously
remove several active ESEs. In fact, any variant of the interval c.202_235 should be consid-
ered as potentially spliceogenic and functionally assayed. For instance, the recognition of
atypical GC donors, which are usually associated with alternative splicing, requires the
binding of several SR proteins such as SC35, Tra2β, 9G8, SF2/ASF and SRp40 [24,48,55].
Alternatively, there have been reported bi-functional SREs with enhancer and silencer
properties such as the composite exonic splicing regulatory elements (CERES) [56,57],
wherein the splicing impact is extremely difficult to predict. Exceptionally, one variant can
decrease and increase in parallel the enhancer and silencer strengths, respectively, resulting
in complete splicing anomalies. This is the case in the synonymous variant c.891C>T of the
SPINK5 gene (MIM #605010), which induces exon 11 skipping. This change reduces the
interaction with enhancing factor Tra2β and concurrently increases the binding of repressor
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hnRNPA1 [58]. Hence, RAD51D c.202G>A, which did not generate any FL transcripts, in
contrast to other close variants (i.e., c.198G>T or c.208G>A), might behave like this SPINK5
variant. Likewise, the spliceogenic variants that we report here might differently alter
the ESE/ESS balance such that they would induce different impacts. Nevertheless, the
participation of any activator/repressor splicing factors should be demonstrated by RNA
binding assays.
With regard to the ESE/ESS prediction approaches, all of them showed advantages
and disadvantages (Tables 2, S5 and S6). HEXplorer showed the highest sensitivity (74.1%)
and accuracy (61.5%) but the lowest specificity (33.3%); in fact, HEXplorer would have
selected most variants of this critical segment (28 variants). However, the estimations
of HSF, HEXplorer, Hot-Skip and ∆tESRseq would have failed in detecting 19, 7, 19
and 17 spliceogenic variants, respectively. For example, c.184T>A, which presented a
moderately strong impact (62.8% of abnormal transcripts), would only have been detected
by the less sensitive program (HSF, 29.6%). Tubeuf et al. [59] evaluated four ESE/ESS
predictors, including ∆tESRseq and HEXplorer, in a large dataset of >1300 variants, wherein
they found greater accuracy of both tools, HEXplorer specificity and ∆tESRseq sensitivity
than in our study. This may be due to the small size of our sample or specific exon/gene
parameters that may affect the performance of SRE predictors, as indicated by these
authors. Nevertheless, the low accuracy of ESE/ESS prediction tools lays bare the need to
improve the detection algorithms. The cumulative knowledge of the splicing regulation
and functional tests could provide a basis for increasing the precision of SRE algorithms
and the prediction of variant impacts. On the other hand, ESE functional mapping by
exonic microdeletions appears as an optimal and reasonable strategy for discovering
SRE hotspots [25,27]. Consequently, we propose to test all the reported variants that are
located in these specific, highly spliceogenic intervals. Furthermore, the identification
of spliceogenic ESE variants should be focused on exons that are targeted by prevalent
alternative events.
4.3. ACMG/AMP-Based Classification of Spliceogenic Variants
Because RAD51D expert panel specifications of the ACMG/AMP guidelines were
not yet available (clinicalgenome.org/, last accessed on 29 December 2020), we developed
our own tentative specifications (Supplementary Methods). Upon doing that, we faced
several challenges, including: (i) combining predictive and functional splicing evidence, (ii)
assigning specific PS3/BS3 code strengths to complex readouts (i.e., two or more mRNA
transcripts with different predicted impacts on the coding sequence), and (iii) integrating a
high level of naturally occurring alternative splicing into the classification system, which
is of particular relevance when evaluating the pathogenicity of VUS [60]. As far as we
know, no specific ClinGen-SVI recommendations addressing these issues have been yet
released [31].
We tackled them by incorporating into the classification system some ad hoc rules
based on structural/functional predictions and expert judgment (e.g., when assigning a
PS3 code strength to complex splicing readouts, we ignored transcripts representing <10%
of the overall expression). Therefore, we do not intend to provide here (see Table 3) a
definitive clinical classification of genetic variants, but rather to highlight some limitations
of the current ACMG/AMP framework to interpret complex spliceogenic outcomes (as in
those observed for several RAD51D variants, see Tables 1 and 2).
However, we think that, overall, our approach produces meaningful classifications,
with spliceogenic variants ending up as variants of uncertain significance if express-
ing either a significant proportion of full-length transcripts (e.g., c.263+6T>C, c.185C>T)
or in-frame transcripts of unknown impact on protein function (e.g., c.476_480+1dup,
c.481-8C>A).
RAD51D c.202G>A is remarkable in that, contrary to most exon 3 variants, full-length
transcripts are not produced. Yet, we have ended up classifying this variant as of uncertain
significance (rather than likely pathogenic) based on: (i) the minigene readout showing a
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significant proportion of in-frame ∆(E3p36) transcripts, and (ii) the variant being detected
in control samples (Table 3). Interestingly, RAD51D c.214T>C produced only full-length
transcripts (therefore, suppressing the level of alternative splicing observed in wt alleles).
The clinical relevance, if any, of suppressing naturally occurring alternative splicing, is
far from obvious. At any rate, canonical transcripts code for a rare missense change
(p.Tyr72His) that warrants classification as of uncertain significance. Indeed, for this
and other RAD51D variants predicted to introduce missense changes and/or in-frame
alterations, additional analyses are required to assess consequences for gene function.
Current ACMG/AMP guidelines [29] have not been developed to identify “intermedi-
ate risk variants”. Yet, we think it is worth considering this possibility for certain variants
expressing variable proportions of (likely) functional and (likely) non-functional mRNAs
(see Table 3 and Supplementary Methods). It will be extremely challenging to evaluate
risk for individual RAD51D variants that are exceedingly rare in the population, but it
should be possible, in principle, to design burden analyses for variants displaying similar
splicing effects.
5. Conclusions
We demonstrated through minigene-based analysis that splicing disruptions were
induced by 28 out of 37 RAD51D variants (75.7%) originally identified in breast cancer
cases and/or healthy controls of the BRIDGES cohort. Functional mapping by exonic
microdeletions was a reliable strategy to identify SRE variants that impaired splicing.
Indeed, using this approach, we identified RAD51D exon 3 sequences in which any genetic
variant (regardless of its predicted coding impact) was a candidate spliceogenic variant.
Finally, we have shown that current ACMG/AMP guidelines raise several issues when
applied to variants associated with complex spliceogenic alterations.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
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